MedPath

Yuhan Corporation

🇰🇷South Korea
Ownership
-
Employees
-
Market Cap
-
Website
menafn.com
·

RYBREVANT® (Amivantamab) Plus Chemotherapy Shows Positive Overall Survival

Updated Phase 3 MARIPOSA-2 study results show RYBREVANT® (amivantamab) plus chemotherapy significantly improves post-progression outcomes and overall survival in previously treated non-small cell lung cancer (NSCLC) patients with EGFR exon 19 deletions or L858R mutations, compared to chemotherapy alone.
globenewswire.com
·

RYBREVANT® (amivantamab) plus chemotherapy shows positive

Updated MARIPOSA-2 study results show amivantamab plus chemotherapy significantly improves post-progression outcomes and overall survival in previously treated NSCLC patients with EGFR exon 19 deletions or L858R mutations, compared to chemotherapy alone.
finance.yahoo.com
·

RYBREVANT® (amivantamab) plus chemotherapy shows positive overall survival trend

Janssen-Cilag International NV announced updated Phase 3 MARIPOSA-2 study results showing RYBREVANT® (amivantamab) plus chemotherapy significantly improved post-progression outcomes and overall survival in previously treated non-small cell lung cancer (NSCLC) patients with EGFR exon 19 deletions or L858R mutations, compared to chemotherapy alone. The data were presented at the ESMO 2024 Congress.
wikileaks-kr.org
·

FDA Approves 'Leklaza' Combination Therapy, What Are the Prospects for Monotherapy in ...

Clinical results show Lecraza monotherapy has a progression-free survival (PFS) of 18.5 months, compared to 16.6 months for Tagrisso, with an objective response rate (ORR) of 83% versus 85%. Yuhan Corporation plans to consult with Johnson & Johnson for FDA approval of Lecraza monotherapy, which could potentially exceed $5 billion in annual sales.
janssen.com
·

Johnson & Johnson is transforming solid tumor cancer outcomes with new findings on RYBREVANT® and TAR-200

Johnson & Johnson presents new findings on RYBREVANT® for lung and colorectal cancers, TAR-200 for bladder cancer at WCLC and ESMO 2024. Highlights include RYBREVANT®'s efficacy in EGFR-mutated NSCLC and its potential in metastatic colorectal cancer, alongside TAR-200's organ-sparing therapy for bladder cancer.
prnewswire.com
·

Johnson & Johnson is transforming solid tumor cancer outcomes with new treatments

Johnson & Johnson presents new findings on RYBREVANT® for lung and colorectal cancers, TAR-200 for bladder cancer, and other treatments at WCLC and ESMO 2024. Highlights include RYBREVANT®'s efficacy in EGFR-mutated NSCLC and its potential in metastatic colorectal cancer, alongside TAR-200's organ-sparing therapy for bladder cancer.
© Copyright 2025. All Rights Reserved by MedPath